Torudokimab
- Generic Name
- Torudokimab
- Drug Type
- Biotech
- CAS Number
- 2241728-76-5
- Unique Ingredient Identifier
- RA1Z27KVB0
- Background
Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With Moderate-to-severe Atopic Dermatitis).
A Study of Different Injectable Formulations of LY3375880 in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 83
- Registration Number
- NCT03913260
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
🇺🇸Covance Clinical Research Inc, Daytona Beach, Florida, United States
A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 136
- Registration Number
- NCT03831191
- Locations
- 🇨🇿
Sanatorium Profesora Arenbergera, Praha 1, Czechia
🇨🇿Clintrial, s.r.o., Praha 10, Hl. M. Praha, Czechia
🇫🇷CHU de Nice Hopital de L'Archet, Nice cedex 3, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath